AbbVie signed a definitive agreement to acquire Landos Biopharma as a step to strengthen its Inflammatory and Autoimmune Disease portfolio through the acquisition of Landos’ lead asset, NX-13
Under the terms of the agreement, AbbVie will acquire Landos for $20.42 per share in cashupon closing adding to an aggregate of $137.5M along with a non-tradable CVR per share with a value of up to $11.14 per share summing to an aggregate of $75M upon achieving clinical development milestone. The transaction is expected to close by Q2’24
NX-13 (250/750mg) is an oral NLRX1 agonist currently being evaluated for safety, efficacy & PK vs PBO in the P-II (NEXUS) clinical trial in patients (n=80) with moderate to severe UC
Ref: AbbVie | Image: AbbVie
Related News:- AbbVie and OSE Immunotherapeutics Join Forces for the Development of OSE-230 to Treat Chronic Inflammation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
